[Study on enhancement of antitumor immunity in cervical cancer--with reference to administration of immunopotentiators].
The immunopotentiator OK-432 was injected intracutaneously, locally, or both, to patients with cervical cancer. The results were as follows: Histological changes: There was a marked increase in the infiltration of T3, Ia1, M1, Leu7 into the interstices surrounding the cancer and the regional lymphnodes. An analysis of the mononuclear cells in the regional lymphnodes by flow cytometry showed an increase in the percentage of M1 and Leu7. Cytotoxicity: There were significant increases in NK activity, LAK activity and killer activity in the mononuclear cells around the cancer and of the regional lymphnodes. These changes in the intracutaneous administration concomitantly with local administration were more marked than in the intracutaneous or local administration.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D007271:Injections, Intradermal; D007694:Killer Cells, Natural / Q000276:immunology; D007962:Leukocytes / Q000473:pathology; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D000276:Adjuvants, Immunologic; D001688:Biological Products; D010844:Picibanil